Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population

Clinical and Experimental Ophthalmology

Volumn 38, Issue 7, 2010, Pages 659-663

  Luu, Susie T ^a   Gray, Timothy ^a   Warrier, Sunil K ^a   Patel, Ilesh ^a   Muecke, James S ^a   Casson, Robert ^a   Gilhotra, Jagjit S ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Age related macular degeneration; Age related maculopathy; Choroidal neovascularization

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; AUSTRALIA; CEREBROVASCULAR ACCIDENT; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; UNSPECIFIED SIDE EFFECT; UVEITIS; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; MIDDLE AGED; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 77958462545     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02309.x     Document Type: Article

References (24)

1. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003; 87: 312-17.
2. Reidy A, Minassian DC, Vafidis G et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 1998; 316: 1643-6.
3. Brown GC, Brown MM, Sharma S et al. The burden of age-related macular degeneration: a value-based medicine analysis. Trans Am Ophthalmol Soc 2005; 103: 173-86.
4. Stevenson MR, Hart PM, Montgomery AM, Mc Culloch DW, Chakravarthy U. Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. Br J Ophthalmol 2004; 88: 1125-30.
5. Congdon N, O'Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-85.
6. Friedman DS, O'Colmain BJ, Tomany MA et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-72.
7. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40: 352-68.
8. Rosenfeld PJ, Mosfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-5.
9. Aisenbrey S, Ziemssen F, Volker M et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-8.
10. Algvere PV, Steen B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol (Copenh) 2008; 86: 482-9.
11. Arevalo JF, Fromow-Guerra J, Sanchez JG et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008; 28: 1387-94.
12. Avery RL, Pieramici CJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
13. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145: 249-56.
14. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143: 510-12.
15. Lazic R, Garbric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 68-73.
16. Madhusudhana KC, Hannan SR, Williams CPR et al. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol 2007; 91: 1716-17.
17. Schouten JS, Heij ECL, Webers CAB, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1-11.
18. Spaide RFM, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-90.
19. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal Bevacizumab and Ranibizumab for Age-related Macular Degeneration. Ophthalmology 2010; 117: 298-302.
20. Tao Y, Libondi T, Jonas JB. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration. J Ocul Pharmacol Ther 2010; 26: 79-83.
21. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-9.
22. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-9.
23. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-7.
24. Alexander S, Linde-Zwirble W, Werther W et al. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology 2007; 114: 2174-8.